(Reuters) - Cempra Inc moved a step closer to approval of its lead antibiotic, solithromycin, after an oral version of the potential blockbuster met the main goal in a late-stage trial.
via Reuters: Health News Read More Here..
via Reuters: Health News Read More Here..
No comments:
Post a Comment